Core Viewpoint - The approval of Tacrolimus extended-release capsules by the National Medical Products Administration of China represents a significant advancement for the company in the immunosuppressive therapy market, enhancing its product portfolio in this area [1][2]. Group 1: Product Approval - The company has received a drug registration approval for Tacrolimus extended-release capsules (0.5mg, 1mg) from the National Medical Products Administration of China [1]. - Tacrolimus is an immunosuppressant that effectively inhibits the formation of cytotoxic lymphocytes responsible for transplant rejection [1]. Group 2: Indications and Mechanism - The product is indicated for the prevention of graft rejection after kidney and liver transplants, as well as for treating graft rejection that cannot be controlled by other immunosuppressive drugs [1]. - The mechanism of action includes the inhibition of T cell activation, proliferation of T helper cell-dependent B cells, and suppression of lymphokine production [1]. Group 3: Market Impact - The approval will further enrich the company's product line in the field of immunosuppressive therapy, positioning it for potential growth in this market segment [2].
石药集团：他克莫司缓释胶囊获药品注册批件